| Alterations of striatal phosphodiesterase 10 A and their association with recurrence rate in bipolar I disorder. | Alterations of striatal phosphodiesterase 10 A and their association with recurrence rate in bipolar I disorder.
Sano Y, Yamamoto Y, Kubota M, Moriguchi S, Matsuoka K, Kurose S, Tagai K, Endo H, Yamagata B, Suzuki H, Tarumi R, Nomoto K, Takado Y, Kawamura K, Zhang MR, Tabuchi H, Mimura M, Uchida H, Higuchi M, Takahata K., Free PMC Article | 10/8/2024 |
| PDE10A Mutation as an Emerging Cause of Childhood-Onset Hyperkinetic Movement Disorders: A Review of All Published Cases. | PDE10A Mutation as an Emerging Cause of Childhood-Onset Hyperkinetic Movement Disorders: A Review of All Published Cases.
Kalampokini S, Xiromerisiou G, Bargiotas P, Anastasiadou VC, Costeas P, Hadjigeorgiou GM. | 08/1/2024 |
| Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders. | Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders.
Bohlega S, Abusrair AH, Al-Qahtani Z, Guzmán-Vega FJ, Ramakrishnan R, Aldosari H, Aldakheel A, Al-Qahtani S, Monies D, Arold ST. | 03/8/2023 |
| Phosphodiesterase 10A (PDE10A) as a novel target to suppress beta-catenin and RAS signaling in epithelial ovarian cancer. | Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer.
Borneman RM, Gavin E, Musiyenko A, Richter W, Lee KJ, Crossman DK, Andrews JF, Wilhite AM, McClellan S, Aragon I, Ward AB, Chen X, Keeton AB, Berry K, Piazza GA, Scalici JM, da Silva LM., Free PMC Article | 11/12/2022 |
| Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling. | Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling.
Luo L, Cai Y, Zhang Y, Hsu CG, Korshunov VA, Long X, Knight PA, Berk BC, Yan C., Free PMC Article | 10/1/2022 |
| Papaverine, a Phosphodiesterase 10A Inhibitor, Ameliorates Quinolinic Acid-Induced Synaptotoxicity in Human Cortical Neurons. | Papaverine, a Phosphodiesterase 10A Inhibitor, Ameliorates Quinolinic Acid-Induced Synaptotoxicity in Human Cortical Neurons.
Bhat A, Tan V, Heng B, Chow S, Basappa S, Essa MM, Chidambaram SB, Guillemin GJ. | 12/18/2021 |
| LINC00473 downregulation facilitates trophoblast cell migration and invasion via the miR-15a-5p/LITAF axis in pre-eclampsia. | LINC00473 downregulation facilitates trophoblast cell migration and invasion via the miR-15a-5p/LITAF axis in pre-eclampsia.
Chi Z, Gao Q, Sun Y, Zhou F, Wang H, Shu X, Zhang M. | 08/21/2021 |
| Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. | Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease.
Farmer R, Burbano SD, Patel NS, Sarmiento A, Smith AJ, Kelly MP., Free PMC Article | 08/14/2021 |
| Mutations in the regulatory GAF domains of PDE10A that cause hyperkinetic syndromes in humans lead to misprocessing of the PDE10A enzyme that ultimately leads to targeted degradation by the ubiquitin proteasome system or clearance by autophagy. Both mechanisms result in a paucity of PDE10A activity that lead to a loss of movement coordination. | Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Tejeda GS, Whiteley EL, Deeb TZ, Bürli RW, Moss SJ, Sheridan E, Brandon NJ, Baillie GS., Free PMC Article | 05/9/2020 |
| PDE10A IgG defines a novel rare neurologic autoimmune syndrome and expands the spectrum of diagnosable paraneoplastic CNS disorders. | Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Zekeridou A, Kryzer T, Guo Y, Hassan A, Lennon V, Lucchinetti CF, Pittock S, McKeon A., Free PMC Article | 02/8/2020 |
| indicate an association between PDE10A and ADCY5 mutations and pre/postsynaptic molecular changes, substantia nigra damage, and white and gray matter changes within the striatocortical pathways | PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.
Niccolini F, Mencacci NE, Yousaf T, Rabiner EA, Salpietro V, Pagano G, Balint B, Efthymiou S, Houlden H, Gunn RN, Wood N, Bhatia KP, Politis M. | 09/14/2019 |
| This report that PDE10A mutation is associated with familial Benign hereditary chorea. | A familial case of PDE10A-associated childhood-onset chorea with bilateral striatal lesions.
Miyatake S, Koshimizu E, Shirai I, Kumada S, Nakata Y, Kamemaru A, Nakashima M, Mizuguchi T, Miyake N, Saitsu H, Matsumoto N. | 05/4/2019 |
| natural selection on genetic variants in the PDE10A gene have increased spleen size in the Bajau population of Indonesia, providing them with a larger reservoir of oxygenated red blood cells | Physiological and Genetic Adaptations to Diving in Sea Nomads.
Ilardo MA, Moltke I, Korneliussen TS, Cheng J, Stern AJ, Racimo F, de Barros Damgaard P, Sikora M, Seguin-Orlando A, Rasmussen S, van den Munckhof ICL, Ter Horst R, Joosten LAB, Netea MG, Salingkat S, Nielsen R, Willerslev E. | 02/16/2019 |
| childhood onset of chorea with normal cognition and striatal hyperintensities should prompt further evaluation beyond benign hereditary chorea and heterozygous or homozygous mutations in PDE10A can cause such a phenotype. More number of cases needs to be identified before a definite phenotype genotype correlation can be made in such cases. | Familial choreoathetosis due to novel heterozygous mutation in PDE10A.
Narayanan DL, Deshpande D, Das Bhowmik A, Varma DR, Dalal A. | 06/23/2018 |
| Results indicate that aging is associated with a considerable physiological reduction of the availability of phosphodiesterase 10A enzyme enzyme in the striatum. | Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D(2/3) receptors and sub-cortical volumes in the human basal ganglia: A PET study with (18)F-MNI-659 and (11)C-raclopride with correction for partial volume effect.
Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, Fitzer-Attas CJ, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A. | 03/10/2018 |
| replication confirmed at genome-wide significance the association of loci at FOXE1 with hypothyroidism, and PDE8B, CAPZB and PDE10A with serum TSH. A total of 12 SNPs seemed to explain nearly 7% of the serum TSH variation | Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a Genetics of Diabetes Audit and Research Tayside study (GoDARTS).
Soto-Pedre E, Siddiqui MK, Doney AS, Palmer CNA, Pearson ER, Leese GP. | 03/10/2018 |
| Collectively, these findings highlight a novel thermoregulatory role for PDE10A in mouse and human adipocytes and promote PDE10A inhibitors as promising candidates for the treatment of obesity and diabetes. | A novel thermoregulatory role for PDE10A in mouse and human adipocytes.
Hankir MK, Kranz M, Gnad T, Weiner J, Wagner S, Deuther-Conrad W, Bronisch F, Steinhoff K, Luthardt J, Klöting N, Hesse S, Seibyl JP, Sabri O, Heiker JT, Blüher M, Pfeifer A, Brust P, Fenske WK., Free PMC Article | 09/16/2017 |
| The method proposed for quantification of [(11)C]Lu AE92686 binding in applied studies in NHP is based on 63 min PET data and SRTM with cerebellum as a reference region. The study supports that [(11)C]Lu AE92686 can be used for PET examinations of PDE10A binding also in substantia nigra. | Characterization of [(11)C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain.
Yang KC, Stepanov V, Amini N, Martinsson S, Takano A, Nielsen J, Bundgaard C, Bang-Andersen B, Grimwood S, Halldin C, Farde L, Finnema SJ., Free PMC Article | 03/11/2017 |
| Studied what regions of the PDE10A gene are transcribed in human putamen and caudate nucleus brain tissue, two sub-regions of the striatum. Surprisingly, twelve novel transcripts were detected, of which three were predicted to be translated into PDE10A proteins with unique N-termini.studies show that there is much more transcript diversity within the PDE10A gene region than initially believed. | Novel PDE10A transcript diversity in the human striatum: Insights into gene complexity, conservation and regulation.
MacMullen CM, Fallahi M, Davis RL. | 01/28/2017 |
| The PDE10A gene is currently known to be comprised of 23 exons26 and maps to chromosome 6q26,17, 18 a region previously associated with bipolar disorder. | Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder.
MacMullen CM, Vick K, Pacifico R, Fallahi-Sichani M, Davis RL., Free PMC Article | 10/22/2016 |
| We have demonstrated that de novo dominant mutations in PDE10A are the cause of a unique movement disorder characterized by benign childhood-onset chorea and typical MRI abnormalities of the striatum. | De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions.
Mencacci NE, Kamsteeg EJ, Nakashima K, R'Bibo L, Lynch DS, Balint B, Willemsen MA, Adams ME, Wiethoff S, Suzuki K, Davies CH, Ng J, Meyer E, Veneziano L, Giunti P, Hughes D, Raymond FL, Carecchio M, Zorzi G, Nardocci N, Barzaghi C, Garavaglia B, Salpietro V, Hardy J, Pittman AM, Houlden H, Kurian MA, Kimura H, Vissers LE, Wood NW, Bhatia KP., Free PMC Article | 09/3/2016 |
| germline PDE10A mutations associated with hyperkinetic movement disorder | Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
Diggle CP, Sukoff Rizzo SJ, Popiolek M, Hinttala R, Schülke JP, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, Sharif SM, Reinhart V, James LC, Vanase-Frawley MA, Charych E, Allen M, Harms J, Schmidt CJ, Ng J, Pysden K, Strick C, Vieira P, Mankinen K, Kokkonen H, Kallioinen M, Sormunen R, Rinne JO, Johansson J, Alakurtti K, Huilaja L, Hurskainen T, Tasanen K, Anttila E, Marques TR, Howes O, Politis M, Fahiminiya S, Nguyen KQ, Majewski J, Uusimaa J, Sheridan E, Brandon NJ., Free PMC Article | 09/3/2016 |
| cGMP PDE isozymes, PDE5 and 10, are elevated in colon tumor cells compared with normal colonocytes, and inhibitors and siRNAs can selectively suppress colon tumor cell growth | Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10.
Li N, Chen X, Zhu B, Ramírez-Alcántara V, Canzoneri JC, Lee K, Sigler S, Gary B, Li Y, Zhang W, Moyer MP, Salter EA, Wierzbicki A, Keeton AB, Piazza GA., Free PMC Article | 08/27/2016 |
| Longitudinal data in a cohort of patients with early Huntington disease found PDE10 to be a useful biomarker of disease progression. | Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caillé F, Alagille D, Morley TJ, Papin C, Seibyl JP, Marek KL. | 07/2/2016 |
| Lu AF33241 represents a novel PDE2A/PDE10A inhibitor tool which can penetrate the blood brain barrier. | Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
Redrobe JP, Rasmussen LK, Christoffersen CT, Bundgaard C, Jørgensen M. | 05/21/2016 |